MondayOct 17, 2022 1:06 pm

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Anticipating 2023 IND Application for Secondary Portfolio Candidate

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical innovator, is currently conducting a potentially pivotal global phase 2 clinical trial in humans to test the effectiveness of its anti-glioblastoma (“GBM”) drug candidate – Berubicin. Testing of Berubicin resulted in a notable success with evidence of improved survival among a dozen safety trial participants recruited by the drug’s original developer over 15 years ago. In its annual stockholder meeting, the company also provided an update for its secondary drug portfolio WP1244. The anthracycline-based substance, being evaluated for the treatment of brain cancers, ovarian and lymphomas, “has produced a new derivative as WP1874 with…

Continue Reading

MondayOct 17, 2022 9:30 am

TinyGemsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Continues to Broaden Reach with Fr8App B2B Marketplace

Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), an over-the-road shipping technology innovator, has developed an AI-powered marketplace solution for optimizing and automating the supply chain process to help keep trucks moving with minimal obstacles. “The company’s Fr8App B2B marketplace is its flagship product in a suite powered by AI and machine learning technology that helps connect shippers with qualified carriers as a real-time broker portal… In the company’s Q2 2022 financial report, Fr8Tech noted that quarterly revenue for the period ended June 30 grew 60% over the Q1 report and was up 45% for the period YoY, establishing a new record for…

Continue Reading

FridayOct 14, 2022 12:29 pm

TinyGemsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Marks Milestone Toward Unique and Uncompromising EV Experience

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, recently announced a partnership with Watergen Inc., an Israel-based company building technology and equipment that create drinking water from the air, to develop and equip Mullen’s portfolio of EVs with technology that will produce fresh drinking water for in-vehicle consumer and commercial application. “Watergen’s technology of ‘air to clean drinking water’ for vehicles can generate a fresh supply of hot and drinking water for vehicle occupants. This technology is envisioned for Mullen’s fleet of EV cargo vans and can be utilized in both commercial and recreational vehicle settings. The air-to-water…

Continue Reading

FridayOct 14, 2022 12:05 pm

TinyGemsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Executes on Several Clinical, Operational Advancements in Pursuit of GBM Treatment

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, recently released its financial results for the second quarter of the fiscal year ended June 30, 2022. “CNS kicked off Q3 2022 with approximately $9 million in cash, and working capital of approximately $10.3 million, which, it is confident, will fund its operations into the 2023 calendar year. Currently, the company is exploring the full potential of its lead product candidate, Berubicin. Results from clinical studies over the last six months have proven fruitful,…

Continue Reading

ThursdayOct 13, 2022 2:49 pm

TinyGemsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Pipeline Addressing Severe Unmet Patient Needs

Lexaria Bioscience Corp. (NASDAQ: LEXX), a biotechnology company focusing its attention and resources on pursuing the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients, developed the patented DehydraTECH(TM) drug delivery technology. “The company has evidenced, through in-vivo, in-vitro and pre-clinical testing, that DehydraTECH delivers more APIs at a faster rate than controls, enabling more effective drug absorption. The testing has so far involved APIs such as cannabidiol (‘CBD’), PDE5 inhibitors, antiviral drugs, and nicotine, each at different stages of product development. This DehydraTECH pipeline, Lexaria says, is addressing severe unmet patient needs. Its DehydraTECH-CBD…

Continue Reading

ThursdayOct 13, 2022 9:57 am

TinyGemsBreaks – Golden Matrix Group Inc. (NASDAQ: GMGI) Posting Increasing Revenues Quarter after Quarter on Strengths of Its B2B, B2C Platforms

Golden Matrix (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems and gaming content, currently supports over 645 operators and 6.8 million players in its B2B business and over 229,000 players in its RKings B2C segment. “GMGI’s next generation GM-Ag System – the industry standard – provides access to 10,000+ games while simplifying payment options via seamless integrations with third-party platforms and digital wallets,” a recent article reads. And as the iGaming market continues its rapid pace, Golden Matrix continues to ride the rising wave of industry growth with non-stop consecutive profitable quarters and record-breaking quarterly revenues. “Our…

Continue Reading

WednesdayOct 12, 2022 2:58 pm

TinyGemsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Partnering to Expedite Exports, Increase Global Market Penetration of Colombian Cannabis Goods

Flora Growth Corp. (NASDAQ: FLGC), a global cannabis brand builder, is increasing the strengths of its supply chain, centered in its 100-hectare (about 247-acre) cultivation facility located in the heart of Colombia’s green climate, by finalizing a three-year distribution agreement with the Misak indigenous tribe’s pharmaceutical arm. “Pharma Indigena Misak Manasr Sas, referred to simply as Manasr, is the tribe’s pharmaceutical enterprise, which in 2020 became the first native community business to receive a license from the national Ministry of Justice for producing legal cannabis for medicinal and scientific use... Flora Growth will assist the tribe with regulatory advice, as…

Continue Reading

FridayOct 07, 2022 2:39 pm

TinyGemsBreaks – Golden Matrix Group Inc. (NASDAQ: GMGI) Rolling out Expansion Strategy to Capitalize on ‘Compelling Opportunities’

Golden Matrix (NASDAQ: GMGI), a developer and licensor of online gaming platforms, systems and gaming content, owns an extensive portfolio of proprietary technology that has made it a leader in B2B solutions. This is evidenced by the company’s record-breaking revenues and non-stop profitable quarters. “Backed by its stellar financial track record, GMGI is moving into the B2C social gaming sector. The company recently purchased an 80% stake in U.K.-based RKingsCompetitions Ltd. in December 2021, with the rights to acquire the remaining 20%. RKings is a prize competition business based in Ireland and the United Kingdom that offers paid and free…

Continue Reading

ThursdayOct 06, 2022 2:31 pm

TinyGemsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Elevating Performance with Expanded Team

Flora Growth Corp. (NASDAQ: FLGC), throughout 2022, has been implementing its hiring strategy that has seen the appointment of several key individuals whose proven talents and productivity are critical to the company’s goal of delivering the most compelling customer experiences. “Flora Growth ushered in the new year with the appointment of Tim Leslie as chairman of its newly formed advisory board. It would later bring Derek Pedro, an industry-leading cannabis genetics and cultivation expert, on board as an advisor and named Vessel founder James Choe as chief strategy officer. In February 2022, Flora Growth announced the appointment of Jessie Casner…

Continue Reading

ThursdayOct 06, 2022 2:15 pm

TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Redefining Drug Delivery Platforms

Lexaria Bioscience Corp. (NASDAQ: LEXX) has remained committed to improving the way active pharmaceutical ingredients (“APIs”) enter the bloodstream. “Moreover, as a global innovator in drug delivery platforms, the company has not shied away from advancing its research to cut across various health conditions, including but not limited to hypertension, epilepsy, diabetes, and dementia, among others. These efforts have yielded 27 granted patents around the world since 2014, with approximately 50 additional patents pending. It also has national filings in over 40 jurisdictions with the highest commercial potential, reflecting the company’s commitment to creating shareholder value and pushing its technology…

Continue Reading

Contact us: (512) 354-7000